Approval · Notice of Compliance 16252 · 2014
VAN-ALENDRONATE: Notice of Compliance 16252
Issued November 5, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16252
- Date
- November 5, 2014
- Company
- Vanc Pharmaceuticals IncRichmond, British Columbia, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Bone metabolism regulator
- Canadian reference product
- FOSAMAX (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VAN-ALENDRONATE | 02428717 | Cancelled Post Market |
| VAN-ALENDRONATE | 02428725 | Cancelled Post Market |
| VAN-ALENDRONATE | 02428733 | Cancelled Post Market |
Medicinal ingredients
- ALENDRONIC ACID 5 MG per TAB
- ALENDRONIC ACID 10 MG per TAB
- ALENDRONIC ACID 70 MG per TAB